Showing recent highlights
What's New
PubMed · July 11, 2026
Researchers found that a newer lupus medication called telitacicept may work better than another lupus drug called belimumab at calming lupus activity and protecting the kidneys — two things that matter a lot for people living with lupus, since kidney damage is one of the most serious complications of the disease. In the studies reviewed, people taking telitacicept were roughly twice as likely to reach a low disease activity state and to show full kidney recovery at six months compared to those taking belimumab. This is early research and hasn't yet changed treatment guidelines.
Ask your doctor: Ask the doctor whether telitacicept might work better than belimumab for treating the patient's lupus symptoms.
What's New
PubMed · July 6, 2026
Researchers found that a drug called anifrolumab helped people with lupus — a condition where the immune system mistakenly attacks the body — in two important ways: it reduced lupus disease activity and allowed many patients to lower their doses of steroids, which can cause serious side effects when taken long-term. In real-world use outside of clinical trials, about 3 in 4 patients reached a state of low disease activity within 6 to 12 months, which means their lupus symptoms were much better controlled. This is early research and hasn't yet changed treatment guidelines.
Ask your doctor: Ask the doctor whether anifrolumab might help the patient's lupus symptoms and whether it could mean needing less of the steroid medications the patient is currently taking.
What's New
PubMed · July 3, 2026
Researchers found that belimumab (a medication used to treat lupus, sold as Benlysta) helped more people with lupus reach a state of low disease activity or near-remission compared to a placebo — meaning their lupus became much calmer and easier to manage. About 32% of people taking belimumab reached a low disease activity state by the end of the study, compared to 21% taking the placebo, and those with more severe lupus at the start seemed to benefit the most. This is early research and hasn't yet changed treatment guidelines.
Ask your doctor: Ask the doctor whether belimumab might help the patient achieve remission or low disease activity in lupus, especially if the patient is trying to reduce steroid use.
What's New
PubMed · July 1, 2026
Researchers found that a new oral medication called enpatoran helped reduce skin symptoms in people with lupus — a disease where the immune system mistakenly attacks the body — compared to those who took a placebo (a dummy pill with no active ingredient). The drug works by blocking certain immune signals, called TLR7 and TLR8, that are thought to drive lupus flares, and it was tested across hundreds of patients in multiple countries over 24 weeks. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 1, 2026
Researchers found that in people with lupus-related kidney disease (where the immune system attacks the kidneys), a medication called belimumab helped reduce certain immune system markers — such as specific antibodies that can harm the body — while improving other protective levels in the blood. The study also identified some early biological signals that may help predict which patients are more likely to respond well to belimumab, which could one day help doctors personalize treatment decisions. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 1, 2026
Researchers found that a specific antibody test — called anti-DFS70 — was once thought to be useful for ruling out lupus, since healthy people seemed to have it more often than people with lupus. However, after combining results from 16 studies covering more than 6,000 people, researchers found that people with lupus and healthy people had the antibody at surprisingly similar rates, meaning the test isn't reliable enough on its own to tell doctors whether someone does or doesn't have lupus. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 1, 2026
A study found that in people with lupus who had kidney involvement (called lupus nephritis) and were in remission — meaning their disease was calm and not causing obvious symptoms — a temporary increase in immune-suppressing medication helped prevent flare-ups from coming back. Researchers noticed that some patients showed signs of disease activity in their blood tests even when they felt fine, and boosting their treatment early appeared to stop kidney and other flares from happening over the following two years. This is early research and hasn't yet changed treatment guidelines.
Guidelines
PubMed · July 1, 2026
According to the American College of Rheumatology (ACR) guidelines, people with lupus (a condition where the immune system mistakenly attacks the body) should be treated consistently with hydroxychloroquine, a commonly used lupus medication, while keeping steroid use as short as possible and starting stronger immune-calming therapies early on. The goal is to get lupus under control quickly — reaching remission (meaning the disease is quiet or very low activity) — to reduce serious long-term harm and death related to the condition. These guidelines apply to both children and adults with lupus, and are meant to help patients and their doctors make well-informed decisions together about the best path forward.
Ask your doctor: Ask the doctor whether the patient's current lupus treatment plan follows the 2025 American College of Rheumatology guidelines and if there are any recommended changes based on how the patient is doing.
What's New
PubMed · July 1, 2026
Researchers found that a drug called deucravacitinib, taken as a pill, appears to calm down certain overactive immune signals in people with lupus — particularly signals driven by a protein called interferon, which is known to fuel inflammation in the disease. The drug seemed to shift immune cell activity in the blood closer to patterns seen in healthy people, which suggests it may be working in ways that could help ease lupus symptoms. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 1, 2026
Researchers found that a specialized immune cell treatment called CAR-T therapy — where a patient's own immune cells are reprogrammed in a lab to target problem cells — showed promising early results for people with lupus, including children. Most patients saw their lupus become less active, and many were able to stay that way without taking immune-suppressing medications, which is a big deal since those drugs can have serious side effects. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 30, 2026
Researchers found that dapagliflozin — a diabetes medication like Jardiance or Invokana — significantly reduced protein leaking into the urine in people with inactive lupus kidney disease, with a 36% reduction compared to just 3.5% in those on standard care alone. This matters because high levels of protein in the urine are a sign that the kidneys are under stress, and reducing it may help protect kidney function over time. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 30, 2026
Researchers found that Asian patients with lupus nephritis — a form of lupus that attacks the kidneys — who took a medication called voclosporin were more likely to see their kidney protein levels return to a healthy range compared to those who didn't take it (90% vs. 57%), and they got there much faster (about 6 months vs. nearly 27 months). The medication was generally well-tolerated, though some patients did experience higher rates of reduced kidney function and high blood pressure compared to the control group. This is early research and hasn't yet changed treatment guidelines.
Lifestyle
PubMed · June 29, 2026
Researchers found that regular exercise — including cardio activities, strength training, or a mix of both, done at a moderate intensity for 8 to 12 weeks — helped people with lupus feel less fatigued, experience less pain, move more easily, and feel less depressed. The exercise did not appear to change how active the lupus disease itself was, but it meaningfully improved how people felt day to day. These findings came from combining the results of 12 separate studies involving 470 people with lupus.
What's New
PubMed · June 26, 2026
Researchers found that poor communication between doctors and Black Americans with lupus — a disease where the immune system mistakenly attacks the body — may be contributing to worse health outcomes in this group, who already face higher risks from the disease compared to others. The review looked at 20 studies and found that better, more tailored conversations between patients and their healthcare providers could help close this gap in care. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 22, 2026
Researchers found that among adults with lupus living in the Middle East and North Africa, survival rates were quite high in the early years — about 94% were still alive at 5 years and 90% at 10 years — but dropped more noticeably over time, reaching around 72% at 20 years. The study also identified several factors linked to a higher risk of death, including kidney problems, serious heart problems like heart attacks or strokes, infections, high blood pressure, diabetes, and being male. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 17, 2026
Researchers found that a newer experimental drug called mosunetuzumab, given as an injection under the skin, appeared to be reasonably safe in a small group of 15 people with lupus — an autoimmune disease where the body's immune system mistakenly attacks healthy tissue. The drug works by targeting certain immune cells (called B cells) that are thought to play a role in driving lupus, and the study found it reduced those cells in a dose-dependent way, meaning higher doses had a stronger effect. This is early research and hasn't yet changed treatment guidelines.
Medications
PubMed · June 6, 2026
A study found that a new medication called dapirolizumab pegol (not yet widely available) helped people with moderate-to-severe lupus — a disease where the immune system mistakenly attacks the body — manage their symptoms better than a placebo (a dummy treatment with no active medicine). Researchers gave the drug through an IV every four weeks on top of patients' usual lupus treatments and tracked results over about a year. This appears to be a new treatment option still being evaluated, not a safety update or an existing recommendation.
What's New
PubMed · June 1, 2026
Researchers found that a rare lung complication of lupus called shrinking lung syndrome — where the lungs gradually lose volume and feel harder to fully inflate — most often showed up in younger women, with shortness of breath being the most common symptom in every single case they reviewed. The condition appears to involve the diaphragm (the muscle just below the lungs that helps with breathing) not moving as fully as it should, making it harder to take deep breaths. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
A study found that women with lupus who watched a contraceptive education video through a mobile app felt more interested in using birth control right after watching it — but four weeks later, they were actually less likely to be using effective birth control compared to women who received in-person counseling, mostly because they didn't follow through with clinic visits to get their chosen method. This suggests that while app-based education can spark interest, having someone available in person may help people act on that interest. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · June 1, 2026
Researchers found that a weekly under-the-skin injection of a drug called anifrolumab helped more adults with moderate to severe lupus get their disease under control compared to a placebo (an inactive treatment) — and some patients were even able to lower their steroid doses at the same time, which matters because long-term steroid use can cause its own health problems. Lupus is an autoimmune condition where the body's immune system mistakenly attacks its own tissues, causing inflammation and flares throughout the body. This is early research and hasn't yet changed treatment guidelines.
Ask your doctor: Ask the doctor whether anifrolumab (Saphnelo) might help reduce the patient's lupus symptoms if the patient's current medicines aren't working well enough.
What's New
PubMed · June 1, 2026
Researchers found that belimumab — a medication used to treat lupus — can be given as an under-the-skin injection to children and teenagers with lupus, with dosing adjusted based on the child's weight. The drug reached similar levels in the body as seen in adults, and the approach appeared to work reasonably well across different weight groups. This is early research and hasn't yet changed treatment guidelines.
Medications
The Lancet · May 29, 2026
Researchers found that a medication called dapirolizumab pegol is being explored as a new treatment option for people with lupus, an autoimmune disease where the body's immune system mistakenly attacks its own tissues. The study looked at how this drug works by targeting a specific part of the immune system to help reduce the disease's activity, which can cause a wide range of symptoms throughout the body. This appears to be a new potential option rather than a safety update or standard recommendation.
Ask your doctor: Ask the doctor whether dapirolizumab pegol might be a treatment option for the patient's lupus, since it works in a new way by targeting CD40.
What's New
The Lancet · May 29, 2026
Researchers found that a new medication called dapirolizumab pegol helped reduce disease activity in people with lupus — meaning patients had fewer or less severe symptoms compared to those who received a dummy treatment. Lupus is a condition where the immune system mistakenly attacks the body's own tissues, so finding new ways to calm that activity is a big deal for people living with it. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · May 23, 2026
A study found that tiny calcium deposits in the spleen — spotted on imaging scans — may sometimes be an early sign of lupus, an autoimmune disease where the immune system mistakenly attacks the body's own tissues. Researchers reviewed 30 cases and noticed a recognizable pattern on scans, and found that these deposits could worsen during lupus flare-ups, occasionally causing the spleen to gradually stop working properly. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · May 22, 2026
Researchers found that among pregnant women with lupus (an immune system condition where the body mistakenly attacks its own tissues), those who took hydroxychloroquine — a common lupus medication — were significantly less likely to develop gestational diabetes (a type of high blood sugar that develops during pregnancy) or have a baby with poor growth in the womb, compared to those who didn't take it. The medication didn't show a clear effect on other pregnancy complications like early delivery or high blood pressure during pregnancy. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · May 19, 2026
Researchers found that a drug called anifrolumab, which works by blocking a protein in the immune system called type I interferon — a protein that is overactive in lupus — showed promising results for people with a rare and difficult-to-treat form of lupus called lupus panniculitis, which causes painful inflammation and damage in the deeper layers of the skin. Across 16 patients, most saw their skin symptoms improve significantly, and many were able to reduce or stop taking steroids, which is meaningful because long-term steroid use carries its own health risks. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · May 15, 2026
Researchers found that people with lupus — an autoimmune disease where the body's immune system attacks its own tissues — appear to be more than twice as likely to develop coronary artery disease (a condition where the arteries that supply blood to the heart become narrowed or blocked) compared to people without lupus. This finding came from combining data across 13 studies involving millions of participants, and was also supported by a type of genetic analysis designed to test whether the link is truly causal, meaning lupus itself may be contributing to the increased heart risk rather than just happening alongside it. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · May 9, 2026
Researchers found that a new oral medication called enpatoran — which works by blocking certain signals in the immune system that are thought to drive lupus — was studied in people with moderate-to-severe lupus across 22 countries. The trial looked at different doses of the drug to see which might work best at reducing lupus disease activity over 24 weeks, compared to a dummy pill. This is early research and hasn't yet changed treatment guidelines.
Medications
PubMed · May 5, 2026
Researchers found that belimumab (brand name Benlysta) — a biologic medication, meaning it's made from living cells and works by targeting a specific part of the immune system — helped children with lupus control their disease better than standard treatment alone. The study found that children taking it had significantly less disease activity, fewer lupus flares (sudden worsening of symptoms), and better kidney outcomes, with 94% of those with kidney-related lupus achieving full remission after 12 months. This is considered a relatively new option, as Benlysta is the first biologic approved specifically for children over age 5 with lupus, and this analysis of real-world data adds to the growing evidence about how well it works over time.
What's New
PubMed · May 5, 2026
Researchers found that a new way of measuring how well lupus is being controlled — called the SLE-DAS Responder Index — did a strong job of predicting which patients were actually feeling better in their daily lives. People whose scores improved by a meaningful amount were also less likely to have a sudden worsening of their lupus (called a flare) and needed less steroid medication over time. This matters because better measuring tools can help doctors more accurately judge whether a treatment is truly working for someone with lupus. This is early research and hasn't yet changed treatment guidelines.
For informational purposes only. Not medical advice. Always consult a physician before making any health decisions.